A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

• ClinicalTrials.gov Identifier: NCT04380805
• Recruitment Status: Completed
• First Posted: May 8, 2020
• Last Update Posted: October 21, 2022
• Sponsor: Akeso
• Collaborator: Akesobio Australia Pty Ltd
• Information provided by (Responsible Party): Akeso

Tracking Information

• First Submitted Date: May 1, 2020
• First Posted Date: May 8, 2020
• Last Update Posted Date: October 21, 2022
• Actual Study Start Date: July 15, 2020
• Actual Primary Completion Date: August 29, 2022 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: May 7, 2020): Objective response rate (ORR) assessed by Independent Radiological Review Committee (IRRC) [ Time Frame: Up to 2 years ]
• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: May 7, 2020)

• ORR assessed by Investigator [ Time Frame: Up to 2 years ]
  The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR per RECIST v1.1.
• Disease control rate (DCR) [ Time Frame: Up to 2 years ]
  The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) based on RECIST Version 1.1.
• Duration of Response (DoR) [ Time Frame: Up to 2 years ]
  Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.
• Progression-free survival (PFS) [ Time Frame: Up to 2 years ]
  Progression-free survival is defined as the time from the start of treatment with AK104 until the first documentation of disease progression or death due to any cause, whichever occurs first.
• Number of participants with adverse events (AEs) [ Time Frame: From the time of informed consent signed through 30 days after the last dose, up to 2 years ]
• Minimum observed concentration (Cmin) of AK104 at steady state [ Time Frame: From first dosing date of AK104 through 30 days post last dose of AK104, up to 2 years ]
• Number of subjects who develop detectable anti-drug antibodies [ Time Frame: From first dosing date of AK104 through 90 days post last dose of AK104, up to 2 years ]

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
• Official Title: A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer
• Brief Summary: This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Recurrent Cervical Cancer
• Metastatic Cervical Cancer

Intervention

Biological: AK104

All subjects will receive AK104 as a single agent at a dose of 6 mg/kg Q2W (Day 1 and Day 15 of each 28 day treatment cycle) via IV infusion.

Study Arms

Experimental: AK104

AK104 monotherapy

Intervention: Biological: AK104

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: October 20, 2022): 30
• Original Estimated Enrollment (submitted: May 7, 2020): 40
• Actual Study Completion Date: September 15, 2022
• Actual Primary Completion Date: August 29, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Able to provide written and signed informed consent and any locally required authorization obtained from the subject/legal representative.
2. Women aged ≥18 years at the time of study entry.
3. Subjects must have histologically or cytologically confirmed recurrent or metastatic squamous carcinoma or adenosquamous carcinoma of the cervix, and meet the following criteria: disease progression confirmed by radiologic imaging during or following prior platinum based doublet chemotherapy, with or without bevacizumab for recurrent or metastatic cervical cancer; No more than 2 prior systemic therapies in the recurrent or metastatic setting.
4. Subjects must have measurable lesions according to RECIST v1.1. The presence of measurable lesions must be confirmed by the IRRC. A previously irradiated lesion is not considered measurable and cannot be selected as a target lesion.
5. Available archived tumor tissue sample - block or a minimum of 10 unstained slides of formalin fixed paraffin embedded [FFPE] tissues - preferably from the most recent biopsy of a tumor lesion collected either at the time of or after the diagnosis of locally advanced, recurrent, and/or metastatic disease has been made.
6. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
7. Life expectancy ≥12 weeks.
8. Adequate organ function.

Exclusion Criteria:

1. Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or the follow-up period of an interventional study.
2. Histological types of cervical cancer other than squamous carcinoma and adeno-squamous carcinoma (eg, adenocarcinoma, small cell carcinoma, clear cell carcinoma, sarcoma, etc).
3. Prior malignancy active within the previous 2 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured, such as basal cell skin cancer, or carcinoma in situ of the breast.
4. Brain/central nervous system (CNS) metastases.
5. Clinically significant hydronephrosis, as determined by the investigator, not alleviated by nephrostomy or ureteral stent
6. Active infections (including tuberculosis) requiring systemic antibacterial, antifungal, or antiviral therapy within 4 weeks prior to the first dose of investigational product.
7. Known history of testing positive for human immunodeficiency virus (HIV) or known active acquired immunodeficiency syndrome.
8. Known active hepatitis B or C infections (known positive hepatitis B surface antigen [HBsAg] result or positive hepatitis C virus [HCV] antibody with detectable HCV ribonucleic acid [RNA] results).
9. Active or prior documented autoimmune disease that may relapse.
10. History of interstitial lung disease or noninfectious pneumonitis, except for those induced by radiation therapies.
11. Patients with clinically significant cardio-cerebrovascular disease.
12. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of toxicities not considered a safety risk.
13. History of severe hypersensitivity reactions to other mAbs.
14. Prior allogeneic stem cell transplantation or organ transplantation.
15. Known allergy or reaction to any component of the AK104 formulation.
16. Receipt of the following treatments or procedures: anticancer small molecule targeted agent within 2 weeks, radiation therapy within 2 weeks, other anticancer therapy within 4 weeks, any major surgery within 4 weeks, any other investigational product or procedure within 4 weeks, or agents with immunomodulatory effect within 2 weeks prior to the first dose of investigational product.
17. Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily doses of prednisone or equivalent) or other immunosuppressive medications within 14 days prior to the first dose of investigational product.
18. Receipt of live attenuated vaccines within 30 days prior to the first dose of investigational product.
19. Prior exposure to any experimental antitumor vaccines, or any agent targeting T-cell costimulation or immune checkpoint pathways (eg, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-CD137 or anti-OX40 antibody, etc).
20. Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.

Sex/Gender

• Sexes Eligible for Study: Female
• Gender Based Eligibility: Yes

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Australia, New Zealand, United States

Administrative Information

• NCT Number: NCT04380805
• Other Study ID Numbers: AK104-201-AU
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Akeso
• Original Responsible Party: Same as current
• Current Study Sponsor: Akeso
• Original Study Sponsor: Same as current
• Collaborators: Akesobio Australia Pty Ltd

Investigators

• Study Chair: Leslie Randall, MD; Virginia Commonwealth University

• PRS Account: Akeso
• Verification Date: October 2022